UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, INC. (State or Other Jurisdiction of Incorporation or Organization) 409 Illinois Street San Francisco, CA 9 ...

FibroGen, Inc. (NASDAQ:FGEN) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants David DeLucia - Head of Corporate FP&A / Investor Relations Enrique Conterno - Chief Executive Officer Thane Wettig - Interim Chief Executive Officer Juan Graham - Chief Financial Officer Chris Chung - Senior Vice President of China Operations Mark Eisner - Chief Medical Officer John Hunter - Chief Scientific Officer Conference Call Participants Jason Gerberry - Bank of America Annabel Samimy - Stife ...

FibroGen Reports Second Quarter 2023 Financial Results August 7, 2023 Forward-Looking Statements 2 This presentation contains forward-looking statements regarding FibroGen's strategy, future plans and prospects, including statements regarding the development and commercialization of the company's product candidates, the potential safety and efficacy profile of its product candidates, and its clinical programs. These forward-looking statements include, but are not limited to, statements under the caption "Up ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, INC. (Exact name of registrant as specified in its charter) Delaware 77-0357827 Securities registered pursuant t ...

FibroGen, Inc. (NASDAQ:FGEN) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Michael Tung - Vice President, Corporate Strategy & Investor Relations Enrique Conterno - Chief Executive Officer Juan Graham - Chief Financial Officer Mark Eisner - Chief Medical Officer John Hunter - Chief Scientific Officer Conference Call Participants Jason Gerberry - Bank of America Andy Hsieh - William Blair Danielle Brill - Raymond James Paul Choi - Goldman Sachs Michael Yee - Jefferies Annabel S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, INC. (Exact name of registrant as specified in its charter) Delaware 77-0357827 (State or Other Jurisdiction of ...

Forward-Looking Statements Forward-looking statements involve known and unknown risks, uncertainties, assumptions, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements, including the other risks and uncertainties that are described in the Risk Factors section of our most recent annual report on Form 10-K or quarterly report on Form 10-Q filed wi ...

FibroGen, Inc. (NASDAQ:FGEN) Q4 2022 Earnings Conference Call February 27, 2023 5:00 PM ET Company Participants Michael Tung - VP of Corporate Strategy and IR Enrique Conterno - CEO Mark Eisner - Chief Medical Officer Juan Graham - CFO Thane Wettig - Chief Commercial Officer Conference Call Participants Andrew Tsai - Jefferies Jason Gerberry - Bank of America Andy Hsieh - William Blair Danielle Brill - Raymond James Yaron Werber - Cowen Annabel Samimy - Stifel Operator Thank you for standing by, and welcome ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission file number: 001-36740 FIBROGEN, INC. (Exact name of registrant as specified in its charter) Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Delaware 77-0357827 (State or other jurisdiction of in ...

FibroGen, Inc. (NASDAQ:FGEN) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Michael Tung - IR Executive Enrique Conterno - CEO & Director Juan Graham - CFO Mark Eisner - EVP & Chief Medical Officer Thane Wettig - EVP & Chief Commercial Officer Christine Chung - SVP, China Operations Conference Call Participants Jason Gerberry - Bank of America Merrill Lynch Jack Padovano - Stifel, Nicolaus & Company Michael Yee - Jefferies Alexander Nackenoff - Raymond James & Associates A ...